A clinician’s guide to ADHD treatment options

Gregory W. Mattingly, Joshua Wilson, Anthony L. Rostain

Research output: Contribution to journalReview articlepeer-review

31 Scopus citations


Attention deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental condition of children and adolescents that often persists into adulthood. Primary care physicians are commonly the first to diagnosis ADHD and initiate a treatment plan with the patient. Guidelines recommend psychostimulant treatment as a first-line therapy in the management plan because it has a substantial impact on alleviating the core symptoms of ADHD. The recent development of a variety of methylphenidate and amphetamine formulations provides many options to meet individual patient lifestyle needs. Liquid, chewable, sprinkled capsule, wearable patch, and orally disintegrating tablet formulations are currently available for patients who may be noncompliant with or have difficulty swallowing traditional pills. This review provides a resource for physicians to identify the stimulant delivery formulation that best suits the patient. Formulations in development are also discussed.

Original languageEnglish
Pages (from-to)657-666
Number of pages10
JournalPostgraduate medicine
Issue number7
StatePublished - Oct 3 2017


  • ADHD
  • amphetamine
  • drug delivery
  • methylphenidate
  • psychiatry
  • psychostimulant


Dive into the research topics of 'A clinician’s guide to ADHD treatment options'. Together they form a unique fingerprint.

Cite this